Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Trimmed by Sicart Associates LLC

Sicart Associates LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 105,930 shares of the biopharmaceutical company’s stock after selling 4,200 shares during the quarter. Gilead Sciences accounts for about 3.5% of Sicart Associates LLC’s holdings, making the stock its 6th biggest position. Sicart Associates LLC’s holdings in Gilead Sciences were worth $9,785,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. Avior Wealth Management LLC boosted its holdings in Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after purchasing an additional 108 shares in the last quarter. Concord Asset Management LLC VA lifted its position in shares of Gilead Sciences by 3.8% during the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 111 shares during the period. TFB Advisors LLC lifted its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after acquiring an additional 116 shares during the period. Sumitomo Life Insurance Co. lifted its position in shares of Gilead Sciences by 0.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after acquiring an additional 117 shares during the period. Finally, FDx Advisors Inc. lifted its position in shares of Gilead Sciences by 2.2% during the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company’s stock valued at $450,000 after acquiring an additional 117 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GILD. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Piper Sandler lifted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Wolfe Research initiated coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. BMO Capital Markets lifted their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Stock Down 0.8 %

Shares of Gilead Sciences stock opened at $91.65 on Friday. The company has a fifty day moving average price of $91.97 and a 200 day moving average price of $83.76. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The stock has a market cap of $114.22 billion, a price-to-earnings ratio of 1,018.33, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the company earned $2.29 EPS. The firm’s revenue was up 7.0% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.36%. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 164,211 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 in the last quarter. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.